Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma
Abstract Activating mutations in NRAS account for 15–20% of melanoma, yet effective anti-NRAS therapies are still lacking. In this study, we unveil the casein kinase 1δ (CK1δ) as an uncharacterized regulator of oncogenic NRAS mutations, specifically Q61R and Q61K, which are the most prevalent NRAS m...
Saved in:
| Main Authors: | Yalei Wen, Hui Wang, Xiao Yang, Yingjie Zhu, Mei Li, Xiuqing Ma, Lei Huang, Rui Wan, Caishi Zhang, Shengrong Li, Hongling Jia, Qin Guo, Xiaoyun Lu, Zhengqiu Li, Xiangchun Shen, Qiushi Zhang, Lu Si, Chengqian Yin, Tongzheng Liu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-11-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-024-54140-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies
by: Valentin Feichtenschlager, et al.
Published: (2025-06-01) -
Loss of Golga7 Suppresses Oncogenic Nras‐Driven Leukemogenesis without Detectable Toxicity in Adult Mice
by: Bo Jiao, et al.
Published: (2025-05-01) -
Targeting CDK4/6 suppresses colorectal cancer by destabilizing YAP1
by: Yalei Wen, et al.
Published: (2025-03-01) -
CK2α-mediated phosphorylation of DUB3 promotes YAP1 stability and oncogenic functions
by: Lei Huang, et al.
Published: (2025-01-01) -
Phosphorylation of USP33 by CDK1 stabilizes the mTORC2 component SIN1
by: Yalei Wen, et al.
Published: (2025-07-01)